^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Melanoma
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Immunother
    Title:

    Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study

    Published date:
    08/14/2020
    Excerpt:
    ...we analyzed real-world outcomes of first-line anti-PD-1 monotherapy in advanced melanoma patients...The median OS of patients normally eligible for phase III trial participation was 31 months (95% CI: 23-not estimable). The BRAF mutation was associated with superior OS.
    DOI:
    10.1097/CJI.0000000000000334